Uncategorized

According to a recent American Psychological Association study, the demand for mental health care has increased, despite the fact that many psychologists say they can no longer accept new patients.
Treatment for illnesses related to trauma and stresses, as well as drug use disorders, are in more demand than therapies for anxiety and depression, which have been popular for three years, according to the 2022 Covid-19 Practitioner Impact Survey. Almost half (46%) of practitioners said they couldn’t keep up with the demand for care, and almost three-quarters (72%) have longer waitlists than before the epidemic. Six out of ten practitioners said they no longer have room for new patients.

On average, psychologists reported contacting more than 15 potential new patients every week.
According to the report, there have been more patients with anxiety disorders and 66% more persons seeking therapy for depression since the outbreak began. Nearly half (47%) reported an increase in demand for drug misuse treatment (up from 43% the previous year), and 64% reported an increase in demand for trauma therapy (up from 62 per cent in 2021). Furthermore, two-thirds of psychologists believe that the intensity of patients’ symptoms would deteriorate by 2022.

“The national mental health crisis persists,” APA CEO Arthur C. Evans Jr., PhD, remarked. “Know that you are not alone if you are struggling. According to psychological science, social support is essential for establishing resilience, therefore if you are experiencing problems receiving care in a timely manner, reach out to others for support and to explore methods to manage.” The poll also found an increase in the need for mental health treatment, especially among young people and healthcare professionals. Adolescents aged 13 to 17 had the greatest rise in patients, with 46% of psychologists reporting increases in the preceding 12 months.

During the same time period, psychologists also observed considerable increases in patients aged 18 to 25 (40%) and children under 13 (38%). According to nearly half (46%) of psychologists, more healthcare professionals have sought therapy since the outbreak began.

“Having timely access to psychological services is critical for addressing the needs of those diagnosed with behavioural health challenges,” said Evans. “But we need to tackle this problem with a variety of solutions, beyond individual therapy. We need to support and expand the workforce, promote integrated behavioural health into primary care, improve mental health literacy, and use technology and innovation to expand the reach and improve efficiency. But critically, we must expand our paradigm for addressing behavioural health – especially if we are to successfully address health disparities – by using more public health strategies to reach people earlier and in the places where they live, work, play and worship,” he said.

As the pandemic recedes and in-person encounters become more common, the percentage of psychologists who visit all patients in person has climbed from 4% in 2021 to 11%.
Telemedicine, on the other hand, is still a feasible choice. According to the poll, more over half of psychologists (58%) presently see some patients remotely and some in person, and 31% report seeing all patients through telehealth (down from 47% in 2021).

Patients from underserved groups, such as those living in rural regions and communities of colour, as well as those who would not otherwise be able to receive treatment, may benefit from telehealth services by increasing access to care. The APA continues to advocate for expanded insurance company telehealth coverage, including audio-only coverage, and reimbursement at the same rate as in-person therapy. More than four in ten (45%) psychologists reported feeling burned out due to the constant demand for mental health treatment. The majority of psychologists reported being able to exercise self-care (77%), maintain a favourable work-life balance (63%), and seek peer guidance or aid to combat burnout.

According to a new study, aerobic exercise can lower the likelihood of cancer metastatic spread by 72%.
According to the researchers, the quantity of glucose (sugar) absorbed by internal organs increases during severe aerobic activity, reducing the amount of energy accessible to the tumour. Two TAU Sackler Faculty of Medicine experts headed the study: Prof. Carmit Levy from the Department of Human Genetics and Biochemistry and Dr. Yftach Gepner from the School of Public Health and the Sylvan Adams Sports Institute. Prof. Levy underlines that the new study has resulted in a highly important discovery by merging scientific know-how from multiple schools at TAU, which may help avoid metastatic cancer – Israel’s biggest cause of death. The research was picked on the cover of the respected journal Cancer Research’s November 2022 issue. Prof. Levy and Dr. Gepner: “Studies have shown that physical activity decreases the incidence of several forms of cancer by up to 35%.”

This beneficial effect is comparable to that of exercise on other illnesses such as heart disease and diabetes. In this study, we discovered that high-intensity aerobic exercise that gets its energy from sugar can lower the risk of metastatic cancer by up to 72 percent. If the overall message to the public has been ‘be active, be healthy,’ we can now explain how aerobic movement might optimise protection of the most aggressive and metastatic cancers.”

The study combined data from healthy human volunteers investigated before and after jogging with an animal model in which mice were trained under a stringent exercise schedule. Human data from an epidemiological research that followed 3,000 people for nearly 20 years revealed that participants who reported frequent high-intensity aerobic activity had 72 percent less metastatic cancer than those who did not engage in physical activity.

The animal model had a similar result, allowing the researchers to uncover the underlying process. They discovered that aerobic activity dramatically decreased the growth of metastatic tumours in the lymph nodes, lungs, and liver by sampling the internal organs of physically fit animals before and after physical exercise, as well as after the injection of malignancy. The researchers believed that this good effect is due to the increased rate of glucose intake caused by exercise in both people and model animals.

Prof. Levy: “Our study is the first to investigate the impact of exercise on the internal organs in which metastases usually develop, like the lungs, liver, and lymph nodes. Examining the cells of these organs we found a rise in the number of glucose receptors during high-intensity aerobic activity – increasing glucose intake and turning the organs into effective energy-consumption machines, very much like the muscles. We assume that this happens because the organs must compete for sugar resources with the muscles, known to burn large quantities of glucose during physical exercise. Consequently, if cancer develops, the fierce competition over glucose reduces the availability of energy that is critical to metastasis.
Moreover, when a person exercises regularly, this condition becomes permanent: the tissues of internal organs change and become similar to muscle tissue. We all know that sports and physical exercise are good for our health. Our study, examining the internal organs, discovered that exercise changes the whole body, so that the cancer cannot spread, and the primary tumor also shrinks in size.”

Dr. Gepner added: “Our results indicate that unlike fat-burning exercise, which is relatively moderate, it is a high-intensity aerobic activity that helps in cancer prevention. If the optimal intensity range for burning fat is 65-70 percent of the maximum pulse rate, sugar burning requires 80-85 percent – even if only for brief intervals. For example: a one-minute sprint followed by walking, then another sprint. In the past, such intervals were mostly typical of athletes’ training regimens, but today we also see them in other exercise routines, such as heart and lung rehabilitation.
Our results suggest that healthy individuals should also include high-intensity components in their fitness programs. We believe that future studies will enable personalized medicine for preventing specific cancers, with physicians reviewing family histories to recommend the right kind of physical activity. It must be emphasized that physical exercise, with its unique metabolic and physiological effects, exhibits a higher level of cancer prevention than any medication or medical intervention to date.”

The study gives information on the early stages of infectious illness and the possibilities for pneumococcal septicaemia prophylaxis. Antimicrobial treatment is used to kill or prevent the growth of microorganisms such as bacteria, fungus, and protozoans. The study, published in the journal Nature Microbiology, reveals how the bacteria that causes pneumonia replicates within our immune system during the early stages of infection.

Professor Marco Oggioni of the University of Leicester’s Department of Genetics and Genome Biology led a team of researchers who discovered that the bacterium Streptococcus pneumoniae (pneumococcus) replicates within a specific subset of immune cells in our bodies – a subset of splenic macrophages – before causing invasive and often fatal disease.

This internal replication shields the bacteria from being destroyed by other immune cells as well as the activity of the most regularly used antibiotics, including those indicated for community-acquired pneumonia in the United Kingdom.
The study also found that antibiotic therapy aimed especially at stopping this phase of intracellular replication can avoid the formation of pneumococcal septicaemia, which is frequent in many pneumonia patients.

Pneumonia is one of the primary causes of infectious illness death, and it is more frequent in some vulnerable populations, such as the very young and the elderly. “Understanding infections is vital in knowing how to effectively treat an illness,” explains Professor Marco Oggioni, an honorary consulting biologist at Leicester Hospitals.

“Our findings demonstrate that we can treat potentially fatal illnesses more successfully with readily accessible drugs.” We believe that by determining how and where bacteria cause disease, we can send a powerful message to the medical community, encouraging the modification of presently used medicines, which might lead to a decrease in disease burden and death in the UK and worldwide.”

Using confocal microscopy, the researchers conducted studies on a number of creatures. This enabled them to label and visualise various immune cells as well as the invading bacteria. As part of this work, the team created a new model that makes use of pig spleens that have been processed for food. This allowed them to examine infection in a human-like model without having to infect a real animal.

According to a research of 11,945 persons in six European countries, those with type 2 diabetes who develop cancer are more likely to be detected with advanced illness if the condition is not frequently tested for.

In a presentation to the 13th European Breast Cancer Conference, Dr Anna Jansana, a postdoctoral researcher at the Nutrition and Cancer Multimorbidity group at the International Agency for Research on Cancer (IARC) in Lyon, France, said that unlike breast and bowel (or ‘colorectal’) cancer, for which routine population screening is available in many countries, cancers such as lung, ovarian and prostate, do not have national screening programmes and were more likely to be diagnosed in people with type 2 diabetes only once the cancer had started to spread (metastasise) beyond the original tumour to other parts of the body.

“Our results underline the importance of paying particular attention to patients with pre-existing diseases of the heart, blood vessels or metabolism, such as type 2 diabetes, so that signs of cancer can be identified at an earlier stage when it is more likely to be treated successfully,” she said.

Until now, it has not been known whether people are at greater risk of having a cancer diagnosed when it is at an advanced stage if they have a pre-existing cardiometabolic disease, such as diabetes, heart disease or stroke.

Dr Jansana and her colleagues identified 11,945 cases of cancer diagnosed between 1992 and 2012 among 400,577 participants in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. They looked at those cases where patients had already been diagnosed with cardiovascular diseases, type 2 diabetes, both or none of these, and conducted analyses based on cancers that could be screened for (breast and colorectal cancer) and cancers for which there were no population-based screening programmes in the six European countries included in the study (all the other cancers).

Overall, during a median (average) 15 years of follow-up, among the 11,945 people diagnosed with cancer, 87% had no pre-existing cardiometabolic diseases at the time they were diagnosed with cancer, 5% of cancers occurred in people with a pre-existing diagnosis of cardiovascular disease, 7% in people with a type 2 diabetes diagnosis and 1% in people with a diagnosis of both cardiovascular disease and type 2 diabetes.

A total of 2,623 people had breast cancer and 1,722 had colorectal cancer. For these two cancers, no statistically significant association was found between a later stage of diagnosis and pre-existing cardiovascular diseases and type 2 diabetes.

However, for the 7,400 cases of non-screened cancers, the researchers found that people who had pre-existing type 2 diabetes had a statistically significant 26% increased risk of being diagnosed when their cancer had metastasised, compared to people who did not have pre-existing cardiometabolic conditions. Twenty-six cases were detected before the cancer had started to spread and 41 cases were detected after it had metastasised.

“The good news is that for patients with breast or colorectal cancer, the national screening programmes seem to be detecting cancer often before it has started to spread, both for those with and without pre-existing diagnoses of cardiovascular disease and type 2 diabetes. Our findings underline the importance of participating in screening when invited,” said Dr Jansana.

“However, for cancers for which there are no national screening programmes, our results may prompt policymakers to broaden the scope of public health recommendations to encompass patients affected by cardiometabolic diseases and cancer. At present, cancer screening guidelines do not include recommendations on cancer screening among people with cardiometabolic diseases. It may be necessary for those involved in healthcare and policymaking to consider whether the recommendations need any adjustment in terms of cancer screening.

“In addition, healthcare professionals should pay special attention to people with pre-existing cardiometabolic conditions. Our findings suggest it might be worth developing interventions and treatments to target the common pathways involved in these non-communicable diseases.”

Lifestyle factors such as diet, alcohol intake, exercise and body weight are known to be associated with the onset of both cancer and cardiometabolic disease. High blood sugar levels that are involved in diabetes have been shown to increase cell signalling by the vascular endothelial growth factor (VEGF), which can lead to more advanced cancers and decreased survival. Other biological mechanisms that both cancer and cardiometabolic disease share include inflammation caused by obesity, a condition called oxidative stress, which can damage DNA and cells, and malfunctioning of sex hormone activity, or insulin-like growth factor-1, which is involved in pre- and post-natal growth, or leptin, which is involved in regulating fat storage.

Strengths of the study are that it includes a large number of people from several European countries and validated, standard methods to diagnose cancer. Limitations are that only the first non-fatal coronary event was made available to EPIC centres, not multiple ones; there were no data on how diabetes was managed, for instance, if metformin was used, which is associated with a lower risk of heart and blood vessel problems and some cancers; four of the EPIC participant countries could not be included in the study due to lack of data on the stage of cancer when it was diagnosed, and on health problems related to diabetes and cardiovascular disease.

Dr Laura Biganzoli, chair of EBCC13 and Director of the Breast Centre at Santo Stefano Hospital, Prato, Italy, was not involved in the research. She said: “These findings, which come from the long-running EPIC study, provide additional valuable evidence for the usefulness of national screening programmes for breast and bowel cancer. The presentation by Dr Jansana shows that screening is successful in detecting these particular cancers at an earlier stage independently from pre-existing cardiometabolic conditions. Unfortunately, this is not the case for other cancers, for which there are no national screening programmes, and which are more frequently detected in advanced stages in patients who present with cardiometabolic disease.

“This is important information to be shared with the medical community but unfortunately, at this stage, no recommendations can be provided on specific monitoring procedures to be implemented in this population, apart from recommending participation in already existing screening programmes.”

A new study at the California Institute of Technology demonstrates how devices implanted into people’s brains have the ability to precisely detect which phrases a tetraplegic participant was just thinking rather than speaking or miming.
“Online internal speech decoding from single neurons in a human participant,” a novel discovery, was presented at the 2022 Society for Neuroscience conference in San Diego. The researchers used the opportunity to show off their brain-machine interfaces (BMIs), which might eventually help speech-impaired patients.

“You may already have seen videos of people with tetraplegia using BMIs to control robotic arms and hands, for example to grab a bottle and to drink from it or to eat a piece of chocolate,” says Sarah Wandelt, a Caltech graduate student in the lab of Richard Andersen, James G. Boswell Professor of Neuroscience and director of the Tianqiao and Chrissy Chen Brain-Machine Interface Center at Caltech.

“These new results are promising in the areas of language and communication. We used a BMI to reconstruct speech,” says Wandelt, who presented the results at the conference on November 13.

Previous research has found that examining brain signals captured from motor regions when a participant whispered or mimed phrases can help anticipate participants’ speech. Internal communication, on the other hand, is far more difficult to foresee since it does not entail any movement, argues Wandelt. “In the past, algorithms that tried to predict internal speech have only been able to predict three or four words and with low accuracy or not in real time,” Wandelt says.

The current study is the most accurate at predicting internal words yet. Brain signals were collected from single neurons in the supramarginal gyrus, which is located in the posterior parietal cortex. In a prior study, the researchers discovered that this brain region represented spoken words.

The team has now expanded their results to include internal speech. The researchers then taught the BMI gadget to distinguish the brain signals produced when the tetraplegic subject talked internally or thought particular phrases. This training session lasted roughly 15 minutes. They then displayed a word on a screen and instructed the participant to speak it internally.

The results indicated that the BMI algorithms could identify eight words with up to 91 percent accuracy.
The research is still in its early stages, but it might benefit people with brain injuries, paralysis, or disorders that impact speech, such as amyotrophic lateral sclerosis (ALS).

“Neurological disorders can lead to complete paralysis of voluntary muscles, resulting in patients being unable to speak or move, but they are still able to think and reason. For that population, an internal speech BMI would be incredibly helpful,” Wandelt says.

“We have previously shown that we can decode imagined hand shapes for grasping from the human supramarginal gyrus,” says Andersen. “Being able to also decode speech from this area suggests that one implant can recover two important human abilities: grasping and speech.”

The researchers also point out that BMIs cannot be used to read people’s minds since the device would have to be trained in each person’s brain independently, and they only operate when the person concentrates on the word.

The National Institutes of Health, the Tianqiao and Chrissy Chen Brain-Machine Interface Center, and the Boswell Foundation financed the study, which is now being peer reviewed but has not yet been published. Aside from Wandelt and Andersen, other Caltech contributors include David Bjanes, Kelsie Pejsa, Brian Lee (PhD ’06), and Charles Liu. Lee and Liu are Caltech visiting associates who also teach at USC’s Keck School of Medicine.

Scripps A novel approach based on nanotechnology has shown promise in early trials for the treatment of autoimmune illnesses, according to research scientists.

The scientists developed “nanoparticles” that resemble cells that only attack the immune cells responsible for an autoimmune response, leaving the rest of the immune system unharmed and functioning normally. Their research was published in the journal ACS Nano.

The nanoparticles significantly postponed, and in some cases even prevented, severe disease in a mouse model of arthritis.

“The potential advantage of this approach is that it would enable safe, long-term treatment for autoimmune diseases where the immune system attacks its own tissues or organs–using a method that won’t cause broad immune suppression, as current treatments do,” says senior study author James Paulson, PhD, Cecil H. and Ida M. Green Chair of Chemistry in the Department of Molecular Medicine at Scripps Research.

Rheumatoid arthritis is an example of an autoimmune illness that develops when the immune system assaults the body’s own tissues or organs. In only the United States, 10 million individuals are thought to be affected by these disorders.

Treatments are available and can benefit many people, but they frequently have unintended adverse effects, including an increased risk of infections and malignancies.

Paulson and his associates have approached the immune system in a more focused manner. Numerous autoimmune disorders are brought on by or made worse by immunological assaults on a particular protein called a “self-antigen” in the patient’s body.

The idea underlying the nanoparticle strategy is to eliminate or deactivate only the immune cells that attack that self-antigen–an approach that could be at least as effective as broad immune suppression, without the side effects.

Autoimmune diseases dominated by immune responses to a single self-antigen include some forms of arthritis, the skin blister disease known as pemphigus and the thyroid ailment Graves’ disease.

The researchers developed nanoparticles that could deactivate two types of immune cells: B cells and T cells, with the help of first author Katarzyna Brzezicka, PhD, a postdoctoral research associate in the Paulson lab, research assistant Britni Arlian, and other lab members.

Each nanoparticle had copies of a target self-antigen on its surface and a sugar-related molecule that can bind to a special “off switch” receptor on B cells called CD22. B cells, which produce antibodies and are specific to different antigens, will effectively shut down if they come into contact with both the antigen they are looking for and the CD22 binding partner at the same time.

Each nanoparticle also was laced with a powerful compound called rapamycin to stimulate the production of immune cells called regulatory T cells.

Treg cells, as they’re also known, are responsible for suppressing other T cells needed to generate an autoimmune attack. The overall aim of the study was to effectively knock out only the B and T cells that recognize the self-antigen, leaving the rest of the B- and T-cell populations intact.

The researchers first demonstrated that their nanoparticle-based strategy could tolerate a chicken protein, ovalbumin, that would otherwise elicit a strong immune response in mice. The strategy was then tested in a widely used mouse model of arthritis in which the mouse immune system is genetically predisposed to attack a self-antigen known as GPI.

The researchers demonstrated that treating mice with GPI-tolerizing nanoparticles at the age of three weeks significantly delayed the development of arthritis symptoms, which would normally appear a week or two later. In fact, approximately one-third of the mice remained arthritis-free for the entire 300-day follow-up period. Tests confirmed that the treatment significantly reduced the mice’s production of anti-GPI antibodies while also increasing their Treg populations.

Paulson says his team plans to follow up these highly promising results with further optimization of the nanoparticle strategy.

“We were able to ‘cure’ a third of these animals in this early demonstration, and I think there’s the potential to combine our nanoparticles with other immune modulator treatments to make it even more effective,” Paulson says. “So that will be our next step–as well as demonstrating our technology against other autoimmune diseases caused by unwanted immune responses to a self-antigen.”

The Central Drugs Standard Control Organization (CDSCO) has given the first intra-nasal COVID vaccination in the world clearance for limited use in life-threatening conditions in people age 18 and older.

This was said on Thursday by Union Minister Dr. Jitendra Singh, who was presiding over a meeting of the Societies of Autonomous Institutions of the Department of Biotechnology. He also announced the historic choice to combine the 14 societies of Biotechnology Institutes into a single society for the sake of practical operation, financial efficiency, and integrated working.

The Minister praised the Department of Biotechnology (DBT) and its PSU, Biotechnology Industry Research Assistance (BIRAC), for helping Bharat Biotech International Limited produce the first intranasal COVID vaccine ever (BBIL).

Dr. Jitendra Singh stated that the Department of Biotechnology, Government of India, and BIRAC supported the product development and clinical testing under the Mission COVID Suraksha Program. This vaccine was authorised for primary 2 dose schedule, homologous booster doses for ages 18 and older in emergency conditions.

Dr Jitendra Singh said, “India’s efforts through Mission COVID Suraksha under the dynamic leadership of Prime Minister Narendra Modi has not only strengthened AtmaNirbhar Bharat but also bolstered India’s status as a worldwide vaccine development and manufacturing centre showcasing the strength of Science and Technology. It is a matter of great pride for the country.”

On November 28, iNCOVACC – the intra-nasal vaccine received both Primary series and Heterologous booster approval, as per a press release by Bharat Biotech International Limited (BBIL).

This vaccine has the double benefit of enabling faster development of variant-specific vaccines and easy nasal delivery that enables mass immunization to protect from emerging variants of concern. It promises to become an important tool in mass vaccinations during pandemics and endemics.

The vaccine is a recombinant replication-deficient adenovirus vector vaccine with a pre-fusion stabilized spike protein. This vaccine candidate was evaluated in Phases 1, 2, and 3 clinical trials with successful results.

It has been specifically formulated to allow intranasal delivery through nasal drops. The nasal delivery system has been designed and developed to be cost-effective in low- and middle-income countries. This vaccine is stable at 2-8 degree celsius for easy storage and distribution.

Large manufacturing capabilities have been established by Bharat Biotech at multiple sites across India, including Gujarat, Karnataka, Maharashtra, and Telangana, with operations pan India.

It has the potential to be a crucial tool for mass immunisation campaigns during pandemics and endemics. Launch dates, prices, and availability will be disclosed in due course following the receipt of this clearance.

Data on product development will be shared with the public and submitted to peer-reviewed journals.

Diabetes patients who have also suffered with COVID-19 may have reason to be concerned. The infection may cause long-term health problems, including an increased risk of heart disease.
Dr. Dinender Singla of the College of Medicine has published a paper in the ‘American Journal of Physiology-Heart and Circulatory Physiology.’ He thoroughly investigated the causes and side effects of COVID-19 on individuals with high-risk diabetes, as well as the virus’s ability to accelerate the condition, causing inflammation and heart failure. He believes that people with diabetes or those inclined to the illness have a hereditary predisposition to post-COVID inflammatory disorders that affect the heart and brain.

“We believe that COVID-19 can alter a person’s genetic makeup which can enhance the proliferation of disease and cause further deterioration in diabetes and associated heart disease,” explained Dr. Singla, who is the Advent Health Chair of Cardiovascular Science at the College of Medicine.

“Our thinking is COVID-19 could have three major long-term effects on patients,
Dr. Singla noted. “One is cognitive dysfunction, which can lead to Alzheimer’s disease. Second, it can enhance diabetes in pre-diabetic patients or pre-diabetic conditions. Third, it can exacerbate complications of diabetes such as cardiomyopathy or muscle dysfunction.”

Dr. Singla hypothesises that certain diabetes patients who were infected with COVID-19 acquired a different cellular makeup in their blood than diabetic individuals who were never infected with COVID. The next phase in his research will be to compare particular cellular variations between

“Our goal is to look into whether there is a difference in blood composition or variations in cytokines – proteins that affect communications between cells – compared to the non-COVID diabetic patients,” Dr. Singla said. “If any differences are noted, then we would need to examine what kind of diseases they could potentially cause or enhance in those patients.”

COVID-19 has infected over 600 million people globally, and while vaccinations have rendered the virus less dangerous than it was two years ago, Dr. Singla says there are still many unsolved issues concerning COVID’s long-term impact on health.

“For example, if someone was genetically predisposed to developing heart disease or Alzheimer’s disease, if that person is affected by COVID-19, will that person develop heart disease or Alzheimer’s earlier than they were predisposed to?” Dr. Singla said. “Also how severe will their disease be and will it be different in people who contracted or did not have COVID-19?” Dr. Singla said he is currently working on securing funding to explore the unanswered questions left in the wake of the virus.

“We want to know will diabetes be present in patients infected with COVID-19 10 or 20 years from now?” Dr. Singla said. “Will they develop a special type of cardiomyopathy or diabetic muscle pain and will those diseases be much more in enhanced? Having this information will allow us to be one step ahead in developing therapeutics and treatments to manage any variations of diseases that may occur.”

The server at the All India Institute of Medical Sciences (AIIMS) in Delhi has been down for the eighth day in a row, and sources say that additional analysts from Delhi are at risk of being fired for violating cyber security now that two of them have already been suspended.

According to the sources, “The sanitizing process started, earlier it was 15 but now 25 out of 50 servers and more than 400 endpoint computers have been scanned. Antivirus uploading has also been started for future safety.” On Tuesday, the AIIMS also issued a statement that the e-Hospital data has been restored, “The eHospital data has been restored on the servers. Network is being sanitized before the services can be restored. The process is taking some time due to the volume of data and large number of servers/computers for the hospital services. Measures are being taken for cyber security.”

“All hospital services, including outpatient, in-patient, laboratories, etc continue to run on manual mode.” it said further.

“The National Investigation Agency (NIA) has also joined the investigation. The India Computer Emergency Response Team (CERT-IN), Delhi Police, Intelligence Bureau, Central Bureau of Investigation (CBI) and Ministry of Home Affairs (MHA) representatives are already probing the incident,” sources told ANI.

The internet services after the recommendations from the investigation agencies will remain blocked in AIIMS Delhi.
Laboratory information system (LIS) database and other dependent databases have been restored.

Earlier AIIMS also issued a fresh set of Standard operating procedures (SOP) which says admission, discharge and transfer of patients will be done manually at the hospital till E-Hospital is down.

“Latest SOPs that have to be followed in manual mode till E-Hospital is down. Admission, discharge and transfer are to be done manually at AIIMS, New Delhi. Indent to be done manually,” the hospital said.

It further said that the death or birth certificates are to be made manually on forms as per instruction from the working committee.

“Only urgent samples to be sent and that too with filled forms. Only urgent investigations are to be sent with forms as per instruction from the working committee,” it added.

Delhi’s All India Institute of Medical Science (AIIMS) reported a failure in its server on November 23, as per officials.